News

Based in Vienna, Austria, Haplogen is a biotechnology company focused on developing therapeutic substances for the treatment and prevention of infection by the common cold virus. The multi-year

In July 2016, Judge William Alsup of the U.S. District Court, Northern District of California, granted a Motion to Dismiss sought by Gilead in the case [Case #

Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to

Ankylosing spondylitis is a painful and progressive type of arthritis, in which some or all of the joints and bones of the spine fuse together. The disease is

The Series C round was led by Deerfield Management while RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors and others made significant new investments in the gene therapy

SB26, also known as TAK-671, is a ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis. Non-clinical GLP safety studies performed in monkeys and rats supported early

This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N- Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in

Aralez has signed an agreement to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals for $110m. In another deal, the company agreed to offload its TOPROL-XL

Onpattro is claimed to be the first-of-its-kind RNAi therapeutic and only FDA-approved treatment for this indication. Earlier, Onpattro secured breakthrough therapy and orphan drug designations from the FDA.